surmount trials tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial SURMOUNT-1 Trial - Cardionerds Twitter

However, it is better absorbed, and the best way to receive it is intravenously

A better understanding of the intersecting pathophysiology of HFpEF and AF reveals therapeutic targets that can address both conditions

In addition, although Mendelian randomization evidence generated using summary data from genome-wide association studies (GWAS) in this analysis shows that some effects of semaglutide treatment on the proteome may be mediated through body weight reduction and reduced T2D liability, analyses of the clinical trial data also support effects of semaglutide beyond those that can be explained by the observed weight loss and HbA 1c reductions

Initially indicated for type 2 diabetes mellitus, Tirzepatide promotes glycemic control and weight loss through incretin-mediated insulin secretion and appetite suppression